WSC 2022

Lys Therapeutics announces to attend the 14th World Stroke Organization Congress (#WSC2022, 26-29 October 2022) in person in #Singapore.

Lys Therapeutics and Institut BB@C – Blood and Brain @ Caen normandie are proud to be presenting during this conference new groundbreaking preclinical data using Lys Therapeutics’s lead candidate in ischemic #stroke.

Dr. Manuel BLANC, CEO, is happy to meet you there.

💪 All together against Stroke and its dramatic consequences.

https://lnkd.in/dUyuWkp6 —

———-
#WSC2022 #WSO #Stroke #neurosciences #clinicaltrials #Research #PublicPrivatePartnership #Collaboration #deeptech #biotech #healthcare #lifesciences #CNS #NeurologicalDiseases #NeurovascularDisorders #stroke #dementia #innovation #MedicalNeeds #LysTherapeutics #Glunomab #Glunozumab

With the World Stroke Organization, ETAP-Lab – Preclinical CRO , CHU de Caen Normandie, Inserm and Inserm Transfert, Université de Caen Normandie, CYCERON, ADNormandie, Lyonbiopôle and Bpifrance.